Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity

被引：38

作者：

Miller, John F. ^{[1
]}

Gudmundsson, Kristjan S. ^{[1
]}

Richardson, Leah D'Aurora ^{[1
]}

Jenkinson, Stephen ^{[4
]}

Spaltenstein, Andrew ^{[1
]}

Thomson, Michael ^{[2
]}

Wheelan, Pat ^{[3
]}

机构：

[1] GlaxoSmithKline Res & Dev Ltd, Dept Med Chem, Infect Dis Ctr Excellence Drug Discovery, Res Triangle Pk, NC 27709 USA

[2] GlaxoSmithKline Res & Dev Ltd, Dept Virol, Infect Dis Ctr Excellence Drug Discovery, Res Triangle Pk, NC 27709 USA

[3] GlaxoSmithKline Res & Dev Ltd, Dept DMPK, Infect Dis Ctr Excellence Drug Discovery, Res Triangle Pk, NC 27709 USA

[4] GlaxoSmithKline Res & Dev Ltd, Dept Biochem & Analyt Pharmacol, Infect Dis Ctr Excellence Drug Discovery, Res Triangle Pk, NC 27709 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2010年 / 20卷 / 10期

关键词：

CXCR4; Isoquinoline; Tetrahydroquinoline; AMD070; HIV; Antiviral; ENTRY INHIBITORS; THERAPY; CORECEPTOR; TYPE-1;

D O I：

10.1016/j.bmcl.2010.03.118

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Using AMD070 as a starting point for structural modification, a novel series of isoquinoline CXCR4 antagonists was developed. A structure-activity scan of alternate lower heterocycles led to the 3-isoquinolinyl moiety as an attractive replacement for benzimidazole. Side chain optimization in the isoquinoline series led to a number of compounds with low nanomolar anti-HIV activities and promising rat PK properties. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：3026 / 3030

页数：5

共 17 条

[1] Anti-HIV therapy: Current and future directions
Agrawal, Lokesh
Lu, Xihua
Jin, Qingwen
Alkhatib, Ghalib
[J]. CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (16) : 2031 - 2055
[2] BRIDGER G, 2004, Patent No. 2004020992
[3] Bridger G., 2004, Preparation of chemokine receptor binding (benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquino-lin-8-yl)amines and related heterocyclic compounds with enhanced efficacy against AIDS and other disorders, Patent No. [US20040019058A1, 20040019058]
[4] BRIDGER GJ, 2003, Patent No. 2003055876
[5] Crystal structure of chemically synthesized [N33A] stromal cell-derived factor 1α, a potent ligand for the HIV-1 "fusin" coreceptor
Dealwis, C
Fernandez, EJ
Thompson, DA
Simon, RJ
Siani, MA
Lolis, E
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (12) : 6941 - 6946
[6] Grande F, 2008, CURR PHARM DESIGN, V14, P385
[7] GUDMUNDSSON K, 2006, Patent No. 2006020415
[8] Imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with potent activity against HIV-1
Gudmundsson, Kristjan S.
Boggs, Sharon D.
Catalano, John G.
Svolto, Angilique
Spaltenstein, Andrew
Thomson, Michael
Wheelan, Pat
Jenkinson, Stephen
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (22) : 6399 - 6403
[9] Amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines as CXCR4 antagonists with potent activity against HIV-1
Gudmundsson, Kristjan S.
Sebahar, Paul R.
Richardson, Leah D'Aurora
Miller, John F.
Turner, Elizabeth M.
Catalano, John G.
Spaltenstein, Andrew
Lawrence, Wendell
Thomson, Michael
Jenkinson, Stephen
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (17) : 5048 - 5052
[10] Mutation of Asp171 and Asp262 of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100
Hatse, S
Princen, K
Gerlach, LO
Bridger, G
Henson, G
De Clercq, E
Schwartz, TW
Schols, D
[J]. MOLECULAR PHARMACOLOGY, 2001, 60 (01) : 164 - 173

← 1 2 →